“It is in the Negev that Jewish scientific talent
and research ability shall be tested.”
Israel’s First Prime Minister
Osnat Ohne, Ph.D.
Chief Executive Officer firstname.lastname@example.org
Dr. Osnat Ohne joined the NIBN as CEO in December 2017, following years of experience in the innovative drug development industry where she held various managerial positions. Most recently, she served as COO at Tiltan Pharma Ltd., and prior to that, she was a Director Project Leader in Global Innovative R&D at Teva Pharmaceutical Industries for 10 years. During her years at Teva, Dr. Ohne led diverse innovative drug development projects, encompassing discovery, preclinical, and clinical development, for different types of drug product and disease indications, including experience in FDA regulations for the NCE and NTE route of developments. At Teva, she was also involved with due diligence and management of diverse academic projects, as well as bio startup companies, both in Israel and abroad, as part of Teva’s New Projects and Innovative Venture Unit. Over the years, Dr. Ohne served, in parallel, as an independent consultant to Israeli venture capitals, university technology transfer units, startup companies, and bio-accelerators, mainly for early stage innovative drug development projects. Dr. Ohne received her Ph.D. in immunology from Tel Aviv University's Sackler Faculty of Medicine’s Department of Microbiology in 2001.
Ron Lahav, Ph.D.
Executive Director - Research and Development email@example.com
Dr. Ron Lahav became the NIBN’s Executive Director of R&D in September 2017. Dr. Lahav received his Ph.D. in biology from Ben-Gurion University of the Negev, and this was followed by a postdoctoral fellowship at Princeton University in the Department of Molecular Biology. He has been in the pharmaceutical industry for nearly 15 years, holding various leadership and executive management positions. After serving as a Senior Scientist at the Canadian company, AnorMed, until its acquisition by Genzyme, Dr. Lahav returned to Israel and joined Quark Pharmaceuticals as Project Director; he was quickly promoted to overseeing all projects in various fields such as CNS and oncology. Dr. Lahav was also the CEO of an incubator stage company called Quiet Therapeutics where he led the company from seed funding to a series C round. Following his position at Quiet, Ron held CEO positions at two early stage companies, SpliSense and ART Therapeutics.
Prof. Michael M. Meijler, Ph.D.
Scientific Executive Director firstname.lastname@example.org
Prof. Michael Meijler obtained his M.Sc. degree in Chemistry from the University of Amsterdam and his Ph.D. degree from the Weizmann Institute of Science, under the supervision of Prof. Abraham Shanzer. He then performed postdoctoral research at Prof. Kim Janda lab at the Scripps Research Institute in La Jolla, California. After spending a year as an assistant professor at the Janda group in 2005, Prof. Meijler joined Ben-Gurion University of the Negev’s Department of Chemistry where he became a full professor in 2015. He has been a member of the NIBN since 2009, and he has served as the chair of the Department of Chemistry since August 2018. His research focuses on understanding chemical communication between bacteria themselves, and between bacteria and other species such as plants, fungi, and animals, in various settings. He is particularly interested in unraveling the role of chemical communication among human pathogens helps them in establishing persistent infections, and this knowledge may aid in the development of new therapeutic avenues to combat antibiotic resistance.
Maya Pitshadze, MBA
Executive Director - Finance email@example.com
Maya Pitshadze holds an Executive MBA from Ben-Gurion University of the Negev and a BA in economics and computer science from Bar Ilan University. Ms. Pitshadze has over 18 years of experience in senior positions in the field of finance, including a position at an international pharmaceutical company. She has been at the NIBN since its founding and established the company’s financial and administrative systems.
David Bonfil, Ph.D.
Executive Director - Intellectual Property firstname.lastname@example.org
Dr. David Bonfil joined the NIBN in February 2020. Dr. Bonfil brings over 12 years of experience as a Patent Attorney, specializing in developing IP strategies in the field of Pharmaceuticals, Biotech, and TTO companies. Previously, he held various managerial positions: Most recently, he served as IP Director at Technion Technology Transfer (T3) Unit, before that, he was the IP Director at Neuroderm - Mitsubishi Tanabe. Additionally, Dr. Bonfil was part of the innovative IP department at Teva Pharmaceutical Industries. During these years, Dr. Bonfil was involved in numerous and diverse innovative and generic IP projects, IP due diligence and in identifying and managing risks for startup companies, both in Israel and abroad. Dr. Bonfil received his Ph.D. in Biochemistry from Tel Aviv University, Faculty of molecular biology and biochemistry, followed by a postdoctoral fellowship at Weizmann Institute of Science in the Department of Molecular Genetics.